ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
By C. Donawho, Yanping Luo, T. Penning, J. Bauch, J. Bouska, Velitchka Bontcheva-Diaz, B. Cox, Theodore DeWeese, L. Dillehay, D. Ferguson and 26 more. Clinical Cancer Research, 2007
755 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/a7f49257abe9bbab9965c44af1416e770c38327a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008, background): “Inhibition of PARP has also been reported to enhance the effects of DNA-damaging anticancer drugs such as temozolomide, platinums, and cyclophosphamide in BRCA1-deficient cells (9).”